Margarita Dranitsyna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margarita Dranitsyna has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- R. R. Niyazov
Center for Scientific Advice Ltd
3 shared publications - A. N. Vasiliev
Centre for Scientific Advice
2 shared publications - E. V. Gavrishina
Centre for Scientific Advice
2 shared publications - Galina M. Viryasova
Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119234 Moscow, Russia
1 shared publication - Ilya Yasny
Inbio Ventures, Odintsovo, Russia
1 shared publication - Petr Talantov
Russian Academy of Sciences Commission for Counteracting the Falsification of Scientific Research, Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 23 June 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- Vol. 17 (9) , 11-20
Approaches to switching between insulin product with different insulin active substance
In health care emergencies, it may be necessary to switch a patient from one medicine to another to ensure continuity of care and to keep the patient stable. Such a switch can sometimes be difficult to achieve, especially in the case of medical products requiring individualized dose selection, such as insulin preparations. In Russia, there are no clear recommendations for switching from one insulin preparation to another in such situations. For this reason, foreign experience of switching from one insulin product to another was analyzed in conditions when the supply of the patient’s main insulin product was interrupted for various reasons. Based on the results of the literature review, it was found that the practice of replacing an insulin preparation based on one active ingredient with an insulin preparation with another active ingredient or an insulin preparation with a certain ratio of active ingredients with an insulin preparation with the same active ingredients but in a different ratio is quite common abroad. The experience obtained by foreign researchers has been systematized, and based on this work, algorithms have been proposed to help make appropriate replacement or switching decisions. Some of the proposed algorithms were further formalized, and recommendations were developed by well-known foreign agencies involved in the regulation of drug circulation, as well as by the World Health Organization. The results of this analysis may help to develop domestic approaches to insulin product replacement in health care emergencies.
- 23 June 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- Vol. 17 (9) , 11-20
Open AccessApproaches to switching between insulin product with different insulin active substance
In health care emergencies, it may be necessary to switch a patient from one medicine to another to ensure continuity of care and to keep the patient stable. Such a switch can sometimes be difficult to achieve, especially in the case of medical products requiring individualized dose selection, such as insulin preparations. In Russia, there are no clear recommendations for switching from one insulin preparation to another in such situations. For this reason, foreign experience of switching from one insulin product to another was analyzed in conditions when the supply of the patient’s main insulin product was interrupted for various reasons. Based on the results of the literature review, it was found that the practice of replacing an insulin preparation based on one active ingredient with an insulin preparation with another active ingredient or an insulin preparation with a certain ratio of active ingredients with an insulin preparation with the same active ingredients but in a different ratio is quite common abroad. The experience obtained by foreign researchers has been systematized, and based on this work, algorithms have been proposed to help make appropriate replacement or switching decisions. Some of the proposed algorithms were further formalized, and recommendations were developed by well-known foreign agencies involved in the regulation of drug circulation, as well as by the World Health Organization. The results of this analysis may help to develop domestic approaches to insulin product replacement in health care emergencies.
- Open Access
- 20 April 2021
- Published by Springer Nature in BMC Medical Ethics
- Vol. 22 (1) , 1-8
Unapproved clinical trials in Russia: exception or norm?
In modern Russia, any clinical investigation of a pharmaceutical for use in humans is subject to prior evaluation and approval by the Ministry of Health and its Central Ethics Committee. Despite this, some researchers and trial sponsors fail to comply, this is particularly true in case of the studies initiated by domestic sponsors or sponsor-investigators and published in Russian language medical journals. This exploratory research aims to discover whether it is a sporadic non-compliance with regulations or a common practice. We searched the Russian language database eLIBRARY for the phrase ‘results of a randomised trial’. We selected publications reporting clinical trials and conducted in Russia. For each of the selected studies, we searched the state register of the approved clinical trials. We assessed whether (1) the investigational medicinal product was approved for marketing in Russia; (2) the therapeutic indications, posology, and administration method in the clinical trial were consistent with the approved labelling; (3) the issue of the journal included an advertisement of the medicinal product in question; and (4) the full description of the methodology corroborated that the clinical trial was randomised, as was stated in the title or Of the 26 selected articles, 22 reported the results of unauthorised clinical trials. Three of those trials were conducted in children. Twenty-one studies reported on data from unauthorised trials for investigational products approved for marketing in Russia. However, in nine cases, the therapeutic indications, posology, or administration method did not match the conditions indicated in the labelling. Moreover, in one case, the unauthorised trial included a drug therapy intervention where the active substance was not approved for use in any medicinal product marketed in Russia. In 14 of the 26 articles, the issue of the journal or the article itself contained an advertisement for the same medicinal product or, in one case, its manufacturer. All publications accompanied by advertisements claimed that the medicinal product in question was efficacious. A substantial fraction of the clinical trials initiated by domestic sponsors and reported in Russian medical journals failed to obtain the mandatory prior evaluation and approval from the regulator. This can affect the rights and well-being of the study participants and the scientific validity of the studies.
- 20 April 2021
- Published by Springer Nature in BMC Medical Ethics
- Vol. 22 (1) , 1-8
Open AccessUnapproved clinical trials in Russia: exception or norm?
In modern Russia, any clinical investigation of a pharmaceutical for use in humans is subject to prior evaluation and approval by the Ministry of Health and its Central Ethics Committee. Despite this, some researchers and trial sponsors fail to comply, this is particularly true in case of the studies initiated by domestic sponsors or sponsor-investigators and published in Russian language medical journals. This exploratory research aims to discover whether it is a sporadic non-compliance with regulations or a common practice. We searched the Russian language database eLIBRARY for the phrase ‘results of a randomised trial’. We selected publications reporting clinical trials and conducted in Russia. For each of the selected studies, we searched the state register of the approved clinical trials. We assessed whether (1) the investigational medicinal product was approved for marketing in Russia; (2) the therapeutic indications, posology, and administration method in the clinical trial were consistent with the approved labelling; (3) the issue of the journal included an advertisement of the medicinal product in question; and (4) the full description of the methodology corroborated that the clinical trial was randomised, as was stated in the title or Of the 26 selected articles, 22 reported the results of unauthorised clinical trials. Three of those trials were conducted in children. Twenty-one studies reported on data from unauthorised trials for investigational products approved for marketing in Russia. However, in nine cases, the therapeutic indications, posology, or administration method did not match the conditions indicated in the labelling. Moreover, in one case, the unauthorised trial included a drug therapy intervention where the active substance was not approved for use in any medicinal product marketed in Russia. In 14 of the 26 articles, the issue of the journal or the article itself contained an advertisement for the same medicinal product or, in one case, its manufacturer. All publications accompanied by advertisements claimed that the medicinal product in question was efficacious. A substantial fraction of the clinical trials initiated by domestic sponsors and reported in Russian medical journals failed to obtain the mandatory prior evaluation and approval from the regulator. This can affect the rights and well-being of the study participants and the scientific validity of the studies.
- Open Access
- 12 February 2021
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 23 (6) , 548-560
Biosimilars: development and investigation using achievements in modern biotechnology
Biosimilars are biological drug products that have an equivalent clinical profile with innovator biotherapeutics but are developed under a reduced program. To this end, specific comparability approaches are followed based on reverse engineering that involves a thorough analysis of the innovator biotherapeutics and the development of the version of the latter, which should be as much as possible similar with respect to structural and functional characteristics with the innovator. This approach includes the evaluation and comparison between the biosimilar and innovator biologic with respect to the molecular structure and impurity profile and of biological activity in in vitro settings as well as pharmacokinetic, pharmacodynamic, and immunogenicity characteristics on human subjects. Where considered necessary, animal studies or phase 3 clinical studies might be performed when residual uncertainties remain in terms of biosimilarity, that could not have been resolved in the previous tests and trials. Any potentially inevitable differences should be insignificant for safety and efficacy. The state-of-the-art methods of biotechnology and analytics, when applied in line with the appropriate scientific and regulatory requirements, can allow developing similar biologics where no difference in the clinical profile exists with the respective innovator product. Available experience demonstrates the lack of major problems due to the incomparability between the biosimilar and corresponding reference biologics when applicable scientific standards and regulatory recommendations are met.
- 12 February 2021
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 23 (6) , 548-560
Open AccessBiosimilars: development and investigation using achievements in modern biotechnology
Biosimilars are biological drug products that have an equivalent clinical profile with innovator biotherapeutics but are developed under a reduced program. To this end, specific comparability approaches are followed based on reverse engineering that involves a thorough analysis of the innovator biotherapeutics and the development of the version of the latter, which should be as much as possible similar with respect to structural and functional characteristics with the innovator. This approach includes the evaluation and comparison between the biosimilar and innovator biologic with respect to the molecular structure and impurity profile and of biological activity in in vitro settings as well as pharmacokinetic, pharmacodynamic, and immunogenicity characteristics on human subjects. Where considered necessary, animal studies or phase 3 clinical studies might be performed when residual uncertainties remain in terms of biosimilarity, that could not have been resolved in the previous tests and trials. Any potentially inevitable differences should be insignificant for safety and efficacy. The state-of-the-art methods of biotechnology and analytics, when applied in line with the appropriate scientific and regulatory requirements, can allow developing similar biologics where no difference in the clinical profile exists with the respective innovator product. Available experience demonstrates the lack of major problems due to the incomparability between the biosimilar and corresponding reference biologics when applicable scientific standards and regulatory recommendations are met.